This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Vaccitech Announces Pricing of Initial Public Offering

Vaccitech Announces Pricing of Initial Public Offering

29 Apr 2021

Oxford, UK – Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public... Read more

Exscientia announces investment of up to $525M

Exscientia announces investment of up to $525M

27 Apr 2021

Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientia’s discretion Financing led by SoftBank Vision Fund 2 Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round.... Read more

Oxford-based machine learning start-up Etcembly secures Private Seed Funding

Oxford-based machine learning start-up Etcembly secures Private Seed Funding

23 Apr 2021

Oxford-based machine learning start-up Etcembly secures Private Seed Funding Updated: Apr 23 Oxford, UK: 23rd April 2021. No embargo. Etcembly Ltd (Etcembly), a company building a platform to decode immune repertoires in health and disease, has closed an oversubscribed seed round with a group of private investors. The founders of Etcembly, Michelle Teng, CEO, and Jacob Hurst, CTO, bring a unique blend of... Read more

New ATDBio grant to improve oligonucleotide synthesis for COVID-19 tests

New ATDBio grant to improve oligonucleotide synthesis for COVID-19 tests

13 Apr 2021

Innovate UK funding as company invests in pandemic-driven expansion 13 APR 2021 ATDBio, a leader in complex oligonucleotide synthesis, has been awarded funding by Innovate UK to develop a new method for rapid, efficient and automatable production of large quantities of oligonucleotides for COVID-19 testing. The £168,130 grant, Improved oligonucleotide synthesis for faster, more accurate COVID-19 testing, will enable the company to... Read more

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

09 Apr 2021

Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More